Journal ArticleEur Heart J · November 7, 2024
Modern cancer therapies greatly improve clinical outcomes for both early and advanced breast cancer patients. However, these advances have raised concerns about potential short- and long-term toxicities, including cardiovascular toxicities. Therefore, unde ...
Full textLink to itemCite
Journal ArticleSci Adv · September 27, 2024
Estrogens regulate eosinophilia in asthma and other inflammatory diseases. Further, peripheral eosinophilia and tumor-associated tissue eosinophilia (TATE) predicts a better response to immune checkpoint blockade (ICB) in breast cancer. However, how and if ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · August 6, 2024
BACKGROUND: Both cancer and cardiovascular disease (CVD) are the leading causes of death worldwide. Although our previous study detected a relationship between CVD and cancer incidence, limited evidence is available regarding the relationship between CVD, ...
Full textLink to itemCite
ConferenceBreast Cancer Res Treat · August 2024
PURPOSE: This study aimed to assess safety and efficacy of a modified KEYNOTE 522 protocol, which incorporated pembrolizumab every 6 weeks, allowing for concomitant dose-dense (14 day) doxorubicin and cyclophosphamide (ddAC). By optimizing this dosing, the ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · July 16, 2024
BACKGROUND: Cardiovascular disease and cancer share a common risk factor: chronic stress/allostatic load (AL). A 1-point increase in AL is linked to up to a 30% higher risk of major cardiac events (MACE) in patients with prostate cancer. However, AL's role ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2024
Survival with operable breast cancer has improved markedly in recent decades, however, treatment-related cardiovascular toxicities threaten to offset these gains. Ovarian function suppression paired with aromatase inhibition, for premenopausal women with h ...
Full textLink to itemCite
Journal ArticleCurrent Treatment Options in Cardiovascular Medicine · January 1, 2024
Purpose of review: Cardio-oncology is a subspecialty of medicine focused on minimizing the risk of cardiovascular (CV) toxicity in patients receiving potentially cardiotoxic cancer therapy. While the literature has previously focused on detection of CV tox ...
Full textCite
Journal ArticleJ Am Heart Assoc · November 7, 2023
Cardiotoxicity is a growing concern in the oncology population. Transthoracic echocardiography and multigated acquisition scans have been used for surveillance but are relatively insensitive and resource intensive. Innovative imaging techniques are constra ...
Full textLink to itemCite
Journal ArticleMolecular oncology · October 2023
Taselisib is a potent β-sparing phosphatidylinositol 3-kinase (PI3K) inhibitor that, with endocrine therapy, improves outcomes in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated (PIK3CAmut) advanced breast cancer. To ...
Full textCite
Journal ArticleEuropean journal of preventive cardiology · September 2023
AimsThis study aimed to characterize the influence of a cancer diagnosis on the use of preventive cardiovascular measures in patients with and without cardiovascular disease (CVD).Methods and resultsData from the Behavioural Risk Factor S ...
Full textCite
Journal ArticleJ Natl Compr Canc Netw · July 2023
BACKGROUND: Racial disparities have been reported for breast cancer and cardiovascular disease (CVD) outcomes. The determinants of racial disparities in CVD outcomes are not yet fully understood. We aimed to examine the impact of individual and neighborhoo ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · June 20, 2023
Background Cyclin-dependent kinase (CDK) 4 and 6 inhibitors have significantly improved survival in patients with hormone receptor-positive metastatic breast cancer. There are few data regarding the epidemiology of cardiovascular adverse events (CVAEs) wit ...
Full textLink to itemCite
Journal ArticleGenome Med · April 26, 2023
BACKGROUND: Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35-40% of patients with HR+/HER2- breast cancer. Preclinically, cancer cells harboring doub ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Pharmacol · October 1, 2022
Cardiometabolic disease (CMD) is the most common preventable cause of death in the world. A number of components are included in the spectrum of CMD, such as metabolic syndrome/obesity, hyperglycemia/diabetes, dyslipidemia, and hypertension, which are inde ...
Full textLink to itemCite
Journal ArticleJACC CardioOncol · September 2022
The field of cardio-oncology was born from the necessity for recognition and management of cardiovascular diseases among patients with cancer. This need for this specialty continues to grow as patients with cancer live longer as a result of lifesaving targ ...
Full textLink to itemCite
Journal ArticleJACC CardioOncol · June 2022
There are nearly 17 million cancer survivors in the United States, including those who are currently receiving cancer therapy with curative intent and expected to be long-term survivors, as well as those with chronic cancers such as metastatic disease or c ...
Full textOpen AccessLink to itemCite
Journal ArticleHematology/oncology and stem cell therapy · March 2022
CDK 4/6 inhibitors, in combination with endocrine therapy, are the standard of care for patients with endocrinesensitive advanced breast cancer. This class of drug, however, is associated with QT prolongation, which serves as a surrogate marker for Torsade ...
Full textCite
Journal ArticleEur Heart J · January 31, 2022
AIMS: The national incidence, risk factors, and associated mortality of atrial fibrillation (AF) in breast cancer patients are unknown. METHODS AND RESULTS: Using the Surveillance, Epidemiology, and End Results-Medicare-linked database, we identified femal ...
Full textLink to itemCite
Journal ArticleEuropean heart journal · January 2022
The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the mitigation and management of CV complications or toxicities of cancer therapies, which ...
Full textCite
Journal ArticleBMJ · December 8, 2021
OBJECTIVE: To evaluate the effectiveness of remote proactive management of toxicities during chemotherapy for early stage breast cancer. DESIGN: Pragmatic, cluster randomised trial. SETTING: 20 cancer centres in Ontario, Canada, allocated by covariate cons ...
Full textLink to itemCite
Journal ArticleJACC: CardioOncology · December 1, 2021
Cancer patients and survivors have elevated cardiovascular risk when compared with noncancer patients. Cardio-oncology has emerged as a new subspecialty to comanage and address cardiovascular complications in cancer patients such as heart failure, atherosc ...
Full textCite
Journal ArticleBMC Fam Pract · November 18, 2021
BACKGROUND: As treatments for cancer have improved, more people are surviving cancer. However, compared to people without a history of cancer, cancer survivors are more likely to die of cardiovascular disease (CVD). Increased risk for CVD-related mortality ...
Full textLink to itemCite
Journal ArticleCJC Open · November 1, 2021
Background: Human epidermal growth factor receptor 2 (HER2) overexpressing malignancies, including breast and gastro-esophageal, are associated with a poor prognosis. The cardiotoxicity of trastuzumab, a HER2-targeting monoclonal antibody, is well establis ...
Full textCite
Journal ArticleZdravstveno Varstvo · October 20, 2021
Aim: With the aim of improving personalized treatment of patients on chemotherapy, the objective of the study was to assess the degree of association between selected Quality of life (QoL) indicators and both clinical and imaging cardiac status indicators ...
Full textCite
Journal ArticleBreast Cancer Res Treat · October 2021
PURPOSE: CompLEEment-1 is a phase 3b trial in an expanded patient population with hormone receptor-positive (HR +), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC), the largest current trial of cyclin-dependent kinase ...
Full textLink to itemCite
Journal ArticleJACC CardioOncol · September 2021
Radiation therapy is a cornerstone of cancer therapy, with >50% of patients undergoing therapeutic radiation. As a result of widespread use and improved survival, there is increasing focus on the potential long-term effects of ionizing radiation, especiall ...
Full textLink to itemCite
Journal ArticleCurr Oncol Rep · August 27, 2021
PURPOSE OF REVIEW: HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of ...
Full textLink to itemCite
Journal ArticleCirculation · July 20, 2021
With the advent of novel cancer therapeutics and improved screening, more patients are surviving a cancer diagnosis or living longer with advanced disease. Many of these treatments have associated cardiovascular toxicities that can manifest in both an acut ...
Full textLink to itemCite
Journal ArticleCurr Oncol Rep · July 14, 2021
PURPOSE OF REVIEW: To give an overview of the role of social media (SoMe) in cardio-oncology during the COVID-19 pandemic. RECENT FINDINGS: SoMe has been critical in fostering education, outreach, awareness, collaboration, dissemination of information, and ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Imaging · June 2021
BACKGROUND: Our goal was to evaluate the ability of cardiovascular magnetic resonance for detecting and predicting cardiac dysfunction in patients receiving cancer therapy. Left ventricular ejection fraction, global and regional strain utilizing fast-strai ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · June 1, 2021
Precision medicine has ushered in a new era of targeted treatments for numerous malignancies, leading to improvements in overall survival. Unlike traditional chemotherapy, many molecular targeted antineoplastic agents are available in oral formulation, lea ...
Full textLink to itemCite
Journal ArticleJ Natl Cancer Inst · May 4, 2021
In response to the coronavirus disease 2019 (COVID-19) pandemic, the Cardio-Oncology and Imaging Councils of the American College of Cardiology offers recommendations to clinicians regarding the cardiovascular care of cardio-oncology patients in this exper ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · May 1, 2021
PURPOSE: APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 to 1.00], P = .045) for patients with earl ...
Full textLink to itemCite
Journal ArticleAnn Oncol · February 2021
BACKGROUND: The phase III SANDPIPER study assessed taselisib (GDC-0032), a potent, selective PI3K inhibitor, plus fulvestrant in estrogen receptor-positive, HER2-negative, PIK3CA-mutant locally advanced or metastatic breast cancer. PATIENTS AND METHODS: Po ...
Full textLink to itemCite
Journal ArticleBreast Cancer Res Treat · December 2020
PURPOSE: Anthracyclines are frequently used in adjuvant treatment for early-stage breast cancer (ESBC). The purpose of this study was to evaluate cardiotoxic effects in the first five years after treatment with different anthracycline-based regimens. METHO ...
Full textLink to itemCite
Journal ArticleCardiooncology · November 27, 2020
BACKGROUND: Re-allocation of resources during the COVID-19 pandemic has resulted in delays in care delivery to patients with cardiovascular disease and cancer. The ability of health care providers to provide optimal care in this setting has not been formal ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · November 10, 2020
The innovative development of cancer therapies has led to an unprecedented improvement in survival outcomes and a wide array of treatment-related toxicities, including those that are cardiovascular in nature. Aging of the population further adds to the num ...
Full textLink to itemCite
Journal ArticleCA Cancer J Clin · November 2020
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a pandemic of unprecedented proportions in the modern era because of its highly contagious nature and impact on human health and society: coronavirus disease 2019 (COVID-19) ...
Full textLink to itemCite
Journal ArticleEur J Heart Fail · November 2020
Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides c ...
Full textLink to itemCite
Journal ArticleEur J Heart Fail · November 2020
This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratificat ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · October 20, 2020
Coronavirus disease 2019 (COVID-19) has emerged as a global pandemic and public health crisis. Increasing waves of intermittent infectious outbreaks have dramatically influenced care among broad populations. Over the past 2 decades, there has been a rapid ...
Full textLink to itemCite
Journal ArticleJ Clin Med · March 25, 2020
Cardio-oncology is an emerging field tasked with identifying and treating cancer therapy related cardiac dysfunction (e.g., cytotoxic agents, immunotherapies, radiation, and hormone therapies) and optimizing the cardiovascular health of cancer patients exp ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Soc Clin Oncol Educ Book · March 2020
Advances in cancer screening and improved treatment approaches have led to an increase in survivorship and, consequently, recognition of an association between cancer treatments and the development of cardiovascular complications. In addition, as the popul ...
Full textLink to itemCite
ConferenceCancer Research · February 15, 2020
AbstractBackground: Trastuzumab (T) has improved patient (pt) outcomes in HER2+ breast cancer (BC) but carries a risk of cardiotoxicity. In the adjuvant setting, guidelines recommend cardiac monitoring (CM) ...
Full textCite
ConferenceCancer Research · February 15, 2020
AbstractBackground: Modern breast cancer (BC) therapies have led to significant improvement in disease free and overall survival, but are associated with off target toxicity including cardiotoxicity. Current ...
Full textCite
Journal ArticleClin Breast Cancer · February 2020
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with backbone endocrine therapy have markedly improved progression-free survival and overall survival over endocrine therapy alone in advanced hormone receptor-positive, HER2-negative (HR+/HER ...
Full textLink to itemCite
Journal ArticleAnn Oncol · February 2020
Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically ...
Full textLink to itemCite
Journal ArticleSemin Oncol · December 2019
Session V of the Colloquium was chaired by Professors Teresa López-Fernández of Spain and Grzegorz Opolski of Poland. The 3 speakers addressed cardio-oncology issues as they relate to both clinical studies and real life situations. Professor Susan Dent dis ...
Full textLink to itemCite
Journal ArticleJACC CardioOncol · December 2019
The discipline of cardio-oncology has expanded at a remarkable pace. Recent developments and challenges to clinicians who practice cardio-oncology were presented at the Global Cardio-Oncology Summit on October 3 to 4, 2019, in São Paulo, Brazil. Here, we p ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · August 15, 2019
BACKGROUND: In breast cancer patients, coincidental detection of CAC at chest CT may be important in determining cardiovascular (CV) outcomes and facilitate CV disease primary prevention strategies. METHODS: 408 consecutive breast cancer patients referred ...
Full textLink to itemCite
Journal ArticleCurr Treat Options Cardiovasc Med · June 15, 2019
PURPOSE OF REVIEW: This paper will focus on novel breast cancer therapies used in clinical practice today, as well as review our understanding of standard therapies and their potential impact on cardiovascular health. RECENT FINDINGS: Established and novel ...
Full textLink to itemCite
Journal ArticleCurr Oncol · June 2019
INTRODUCTION: Cardiovascular disease is the 2nd leading cause of long-term morbidity and mortality in cancer survivors. Cardio-oncology clinics (cocs) have emerged to address the issue; however, there is a paucity of data about the demographics and clinica ...
Full textLink to itemCite
Journal ArticleCurr Oncol · June 2019
BACKGROUND: Clinical trials have demonstrated an increased risk of cardiotoxicity in patients with breast cancer (bca) receiving trastuzumab-based therapy. Diabetes, dyslipidemia, and obesity are known risk factors for cardiovascular disease. Studies have ...
Full textLink to itemCite
Journal ArticleCurr Treat Options Cardiovasc Med · May 31, 2019
PURPOSE OF REVIEW: To review cardiotoxicity of and strategies to prevent cardiotoxicity from anthracyclines and anti-HER2 agents used to treat breast cancer. RECENT FINDINGS: Although not common, cardiotoxicity from anthracyclines and anti-HER2 therapies i ...
Full textLink to itemCite
Journal ArticleJ Eval Clin Pract · April 2019
OBJECTIVE: The three Magee Equations provide an estimate of the Oncotype DX recurrence score using commonly available clinicopathologic information (tumour size, grade, oestrogen receptor, progesterone receptor, HER2, and Ki67). We assessed whether integra ...
Full textLink to itemCite
Journal ArticleChronic Illn · March 2019
OBJECTIVES: Shared medical appointments are group appointments, with an optional individual consultation, for patients diagnosed with chronic illnesses. Shared medical appointments improve diabetes management, but little is known about their use for other ...
Full textLink to itemCite
Journal ArticleCurr Oncol · February 2019
Trastuzumab is the standard treatment in Canada for patients with breast cancer positive for her2 (human epidermal growth factor receptor 2), dramatically improving outcomes in that patient group. However, its current intravenous (IV) administration is ass ...
Full textLink to itemCite
Journal ArticleJ Cancer · 2019
Inflammatory breast cancer (IBC) is an understudied and aggressive form of breast cancer with a poor prognosis, accounting for 2-6% of new breast cancer diagnoses but 10% of all breast cancer-related deaths in the United States. Currently there are no ther ...
Full textOpen AccessLink to itemCite
Journal ArticleCurr Oncol · December 2018
Breast cancer is the most common cancer in women, with 15%-25% of those tumours overexpressing the human epidermal growth factor receptor 2 (her2), which is associated with more aggressive disease. On rare occasions, patients present with a paraneoplastic ...
Full textLink to itemCite
Journal ArticleIJC Heart and Vasculature · March 1, 2018
Background: The identification of coronary artery calcification (CAC) detected coincidentally on chest CT exams could assist in cardiovascular risk assessment but may not be reported consistently on clinical studies. Cardiovascular risk factor stratificati ...
Full textCite
Journal ArticleCirculation · February 20, 2018
Cardiovascular disease (CVD) remains the leading cause of mortality in women, yet many people perceive breast cancer to be the number one threat to women's health. CVD and breast cancer have several overlapping risk factors, such as obesity and smoking. Ad ...
Full textLink to itemCite
Journal ArticleBreast Cancer Res Treat · January 2018
BACKGROUND: Pelareorep, a serotype 3 reovirus, has demonstrated preclinical and early clinical activity in breast cancer and synergistic cytotoxic activity with microtubule targeting agents. This multicentre, randomized, phase II trial was undertaken to ev ...
Full textLink to itemCite
Journal ArticleCardio-Oncology · December 1, 2017
Background: Patients with cancer treatment-related cardiotoxicity, which may manifest as heart failure (HF), can present with dyspnea. Nurses frequently assess, triage and offer self-care strategies to patients experiencing dyspnea in both the cardiology a ...
Full textCite
Journal ArticleCurr Oncol · October 2017
INTRODUCTION: Patients with breast cancer (bca) who overexpress her2 (the human epidermal growth factor receptor 2) are at risk for cardiotoxicity when treated with anthracycline-based chemotherapy and her2-targeted agents. The Framingham risk score (frs) ...
Full textLink to itemCite
Journal ArticleClin Pharmacokinet · September 2017
OBJECTIVE: The aim of this study was to evaluate the pharmacokinetics (PK) of trastuzumab emtansine (T-DM1) and relevant analytes in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and hepatic impairment. MET ...
Full textLink to itemCite
Journal ArticleCurr Oncol · June 2017
BACKGROUND: Trastuzumab has improved survival for women with her2-positive breast cancer, but its use is associated with an increased risk of cardiotoxicity. With increased survivorship, the long-term effects of cancer treatment are an important considerat ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · March 10, 2017
Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual survival of the patient with cancer. The purpose of this effort w ...
Full textLink to itemCite
Chapter · January 1, 2017
Cardiotoxicity is now the second leading cause of long-term morbidity and mortality among cancer survivors. The discipline of cardio-oncology has developed in response to the combined decision-making necessary to optimize the care of patients with cancer, ...
Full textCite
Journal ArticleCan J Cardiol · July 2016
Modern treatment strategies have led to improvements in cancer survival, however, these gains might be offset by the potential negative effect of cancer therapy on cardiovascular health. Cardiotoxicity is now recognized as a leading cause of long-term morb ...
Full textLink to itemCite
Journal ArticleCA Cancer J Clin · July 2016
Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of morbidity and mortality in the industrialized world. Modern treatment strategies have led to an improvement in the chances of surviving a diagnosis of cancer; however, the ...
Full textLink to itemCite
Journal ArticleSupport Care Cancer · July 2016
BACKGROUND: The US Oncology Trial 9735 (doxorubicin and cyclophosphamide (AC) versus docetaxel and cyclophosphamide (TC)) reported febrile neutropenia (FN) in 5 % of patients receiving TC chemotherapy, in the absence of routine primary prophylaxis with gra ...
Full textLink to itemCite
Journal ArticleJ Card Fail · June 2016
There is an increasing awareness and clinical interest in cardiac safety during cancer therapy as well as in optimally addressing cardiac issues in cancer survivors. Although there is an emerging expertise in this area, known as cardio-oncology, there is a ...
Full textLink to itemCite
Journal ArticleJAMA Oncol · June 1, 2016
IMPORTANCE: The expense and lengthy follow-up periods for randomized clinical trials (RCTs) of adjuvant systemic therapy in breast cancer make them impractical and even impossible to conduct. Randomized clinical trials of neoadjuvant systemic therapy for b ...
Full textLink to itemCite
Journal ArticleBreast Cancer Res Treat · May 2016
In murine models, overexpression of the MET receptor transgene induces tumors with human basal gene expression characteristics supporting MET inhibition as a treatment strategy for triple-negative breast cancer (TNBC). Foretinib is an oral multi-kinase inh ...
Full textLink to itemCite
Journal ArticleJAMA Oncol · February 2016
IMPORTANCE: Despite multiple patient-centered factors being associated with the risk of chemotherapy-induced nausea and vomiting (CINV), these factors are rarely considered when making antiemetic recommendations. OBJECTIVE: To compare risk model-guided (RM ...
Full textLink to itemCite
Journal ArticleCurrent Oncology · January 1, 2016
Introduction The accrual rate to clinical trials in oncology remains low. In this exploratory pilot study, we prospectively assessed the role that engaging a referring surgeon plays in enhancing nonsurgical oncologic clinical trial accrual. Methods Newly d ...
Full textCite
Journal ArticleBreast Cancer Res Treat · January 2016
Previous studies suggest switching from pamidronate to a more potent bone-targeted agent is associated with biomarker and palliative response in breast cancer patients with bone metastases. Until now, this has not been addressed in a double-blind, randomiz ...
Full textLink to itemCite
Journal ArticleProgress in Pediatric Cardiology · November 1, 2015
While advances in breast cancer treatment, including targeted therapies, have improved patient outcomes, such treatments may be associated with both short and long term toxicity. In 2008, The Ottawa Hospital cardiac oncology clinic was established with the ...
Full textCite
Journal ArticleCMAJ · September 8, 2015
BACKGROUND: Practice guidelines recommend that imaging to detect metastatic disease not be performed in the majority of patients with early-stage breast cancer who are asymptomatic. We aimed to determine whether practice patterns in Ontario conform with th ...
Full textLink to itemCite
Journal ArticleEur J Cancer · September 2015
The PHARE trial was initially reported in 2013 and demonstrated that 6 months of Trastuzumab therapy was inferior to 12 months of therapy in terms of reducing risk of Her2+ breast cancer recurrence. Updated results of this study have been presented and dem ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · May 10, 2015
PURPOSE: The efficacy of lapatinib versus trastuzumab combined with taxanes in the first-line setting of human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (BC) is unknown. PATIENTS AND METHODS: The MA.31 trial compared a co ...
Full textLink to itemCite
Journal ArticleCurr Oncol · March 2015
The Breast Cancer Disease Site Group of Cancer Care Ontario identified the need for new guidelines for the adjuvant systemic therapy of early-stage breast cancer. The specific question to be addressed was "What is the optimal adjuvant systemic therapy for ...
Full textLink to itemCite
Journal ArticleCurr Oncol · March 2015
BACKGROUND: This systematic review addresses the question "What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer?" METHODS: The medline and embase databases were sea ...
Full textLink to itemCite
Journal ArticleCurr Oncol · March 2015
BACKGROUND: Cancer Care Ontario's Program in Evidence-Based Care (pebc) recently created an evidence-based consensus guideline on the systemic treatment of early breast cancer. The evidence for the guideline was compiled using a systematic review to answer ...
Full textLink to itemCite
Journal ArticleCurr Oncol · March 2015
BACKGROUND: The Program in Evidence-Based Care (pebc) of Cancer Care Ontario recently created an evidence-based consensus guideline on the systemic treatment of early breast cancer. The evidence for the guideline was compiled using a systematic review to a ...
Full textLink to itemCite
Journal ArticleCurrent Oncology · March 1, 2015
Questions 1. In female patients with locally advanced breast cancer (LABC) and good response to neoadjuvant chemotherapy (NACT), including endocrine therapy, what is the role of breast-conserving surgery (BCS) compared with mastectomy? 2. In female patient ...
Full textCite
Journal ArticleJ Med Econ · March 2015
OBJECTIVE: The NeoSphere trial demonstrated that the addition of pertuzumab to trastuzumab and docetaxel for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early breast cancer (eBC) resulted in a significant improvement in pa ...
Full textLink to itemCite
Journal ArticleJ Oncol Pract · March 2015
PURPOSE: Adjuvant chemotherapy is considered standard care for patients with lymph node (LN) -positive and high-risk LN-negative early breast cancer (EBC). Although chemotherapy-associated toxicities are documented in clinical trials, the impact of toxicit ...
Full textLink to itemCite
Journal ArticleJournal of Oncology · January 1, 2015
Cardiotoxicity is the second leading cause of morbidity and mortality in cancer survivors. The objective of this international cardiac oncology survey was to gain a better understanding of current knowledge and practice patterns among HCPs involved in the ...
Full textCite
Journal ArticleJournal of Oncology · January 1, 2015
Cardiotoxicity is the second leading cause of long-Term morbidity and mortality among cancer survivors. The purpose of this retrospective observational study is to report on the clinical and cardiac outcomes in patients with early stage and advanced cancer ...
Full textCite
Journal ArticleCurrent Oncology · January 1, 2015
The pi3k/Akt/mtor (phosphatidylinositol 3 kinase/ Akt/mammalian target of rapamycin) signalling pathway is an established driver of oncogenic activity in human malignancies. Therapeutic targeting of this pathway holds significant promise as a treatment str ...
Full textCite
Journal ArticleEur J Cancer · October 2014
BACKGROUND: Oncotype DX recurrence score is a multi-gene assay which quantifies the risk of distant recurrence in patients with hormone receptor-positive (HR+) early breast cancer (EBC) treated with tamoxifen, and predicts the magnitude of clinical benefit ...
Full textLink to itemCite
Journal ArticleBreast Cancer Res Treat · April 2014
The optimal frequency of intravenous (IV) bisphosphonate administration is unclear. We thus performed a study evaluating the effects of switching from 3-4 to 12 weekly therapy in patients with biochemically defined low-risk bone metastases. Patients with s ...
Full textLink to itemCite
Journal ArticleCurr Opin Support Palliat Care · March 2014
PURPOSE OF REVIEW: Although neoadjuvant therapy (NAT) has become a popular approach in the systemic management of breast cancer, several important clinical questions remain unanswered. In this article, we review the literature pertaining to these questions ...
Full textLink to itemCite
Journal ArticleOncologist · February 2014
OBJECTIVE: Our objective was to evaluate preferences associated with grade I/II and grade III/IV chemotherapy side effects among breast cancer patients receiving chemotherapy. We also assessed trade-offs that patients are willing to make between treatment ...
Full textLink to itemCite
Journal ArticleWorld Journal of Clinical Oncology · January 1, 2014
AIM: To show a new paradigm of simultaneously testing whether breast cancer therapies impact other causes of death. METHODS: MA.14 allocated 667 postmenopausal women to 5 years of tamoxifen 20 mg/daily ± 2 years of octreotide 90 mg, given by depot intramus ...
Full textCite
Journal ArticleCurrent Oncology · January 1, 2014
Background Male breast cancer (bc) is a rare disease, and the availability of information on treatment outcomes is limited compared with that for female bc. The objective of the present study was to compare disease-free (dfs) and overall survival (os) for ...
Full textCite
Journal ArticleOncology Letters · January 1, 2014
Platinum-based chemotherapy regimens are frequently used in patients with triple-negative breast cancer (TNBC). The aim of the current study was to assess whether or not platinum-based chemotherapy is associated with an increased time to progression when c ...
Full textCite
Journal ArticleInvest New Drugs · December 2013
PURPOSE: AT9283 is a potent inhibitor of the mitotic regulators, Aurora-kinases A and B, and has shown anti-tumor activity in patients with solid and haematological malignancies. This phase I study assessed safety, tolerability, pharmacokinetic and pharmac ...
Full textLink to itemCite
Journal ArticleBreast Cancer Res Treat · November 2013
Perceptions among women with breast cancer about the relative importance of different potential chemotherapy side effects is not well understood. A survey was performed by women receiving chemotherapy for breast cancer. Grade I/II (mild to moderate) and II ...
Full textLink to itemCite
Journal ArticleCancer Treat Rev · October 2013
Targeting human epidermal growth factor receptor 2 (HER2) during or in sequence with chemotherapy improves overall survival in metastatic and early HER2-overexpressing breast cancer. In this paper we systematically review neoadjuvant clinical trial data in ...
Full textLink to itemCite
Journal ArticleBreast Cancer Res Treat · August 2013
The goal of this project was to investigate the contentious issue of a possible effect of endocrine therapy (ET) on sexual dysfunction (SD) in postmenopausal early stage breast cancer survivors. To date, few studies have assessed sexual functioning prior t ...
Full textLink to itemCite
Journal ArticleJ Support Oncol · March 2013
BACKGROUND: Even with modern antiemetic regimens, up to 20% of cancer patients suffer from moderate to severe chemotherapy-induced nausea and vomiting (CINV) (> or = grade 2). We previously developed chemotherapy cycle-based risk predictive models for > or ...
Full textLink to itemCite
Journal ArticleCurrent Oncology · January 1, 2013
Background Nab-paclitaxel is a solvent-free, taxane-based chemotherapy approved for the treatment of metastatic breast cancer (mbc). This study reports clinical benefit and toxicities experienced by women with mbc treated with nab-paclitaxel at the Ottawa ...
Full textCite
Journal ArticleCardiology Research and Practice · December 1, 2012
Background. We established a dedicated cardiac oncology clinic in 2008 for the rapid diagnosis and treatment of cardiotoxicity related to cancer therapy. In this retrospective observational study, we report on clinical outcomes in women with early-stage br ...
Full textCite
Journal ArticleCurrent Oncology · January 1, 2012
Background Despite the use of standardized anti-emetic guidelines, up to 20% of cancer patients suffer from moderate-to-severe chemotherapy-induced nausea and vomiting (CINV)-that is, grade 2 or greater according to the U.S. National Cancer Institute Commo ...
Full textCite
Journal ArticleCurrent Oncology · January 1, 2012
Background: Use of granulocyte colony-stimulating factor (g-CSF) as primary prophylaxis against chemotherapy-induced neutropenia has significant cost implications. We examined use of g-csf for early-stage breast cancer patients at our centre. The study als ...
Full textCite
Journal ArticleCurrent Oncology · January 1, 2012
Background: Approximately 10% of new breast cancer patients will present with overt synchronous metastatic disease. The optimal local management of those patients is controversial. Several series suggest that removal of the primary tumour is associated wit ...
Full textCite
Journal ArticleJ Clin Oncol · December 20, 2011
PURPOSE: An Institute of Medicine report recommends that patients with cancer receive a survivorship care plan (SCP). The trial objective was to determine if an SCP for breast cancer survivors improves patient-reported outcomes. PATIENTS AND METHODS: Women ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · October 10, 2011
PURPOSE: Somatostatin analogs act directly on breast cancer cells and indirectly on insulin and insulin-like growth factor 1 (IGF-1) levels. This trial was undertaken to assess whether octreotide would lower insulin and IGF-1 levels and reduce risk of brea ...
Full textLink to itemCite
Journal ArticleBreast Cancer Res Treat · October 2011
Biopsies of metastatic tissue are increasingly being performed. Bone is the most frequent site of metastasis in breast cancer patients, but bone remains technically challenging to biopsy. Difficulties with both tissue acquisition and techniques for analysi ...
Full textLink to itemCite
Journal ArticleBreast Cancer Res Treat · April 2011
Aromatase inhibitors (AIs) have been shown to reduce the risk of breast cancer recurrence and are widely used today as adjuvant therapy in women with early stage endocrine-responsive breast cancer. Aromatase inhibitors may be prescribed as initial hormonal ...
Full textLink to itemCite
Journal ArticleCurrent Oncology · January 1, 2011
The inaugural Canadian Cardiac Oncology Network conference was held at the Ottawa Convention Centre, Ottawa, Ontario, May 13, 2011. The learning objectives of the meeting were to • understand and appreciate the importance of cardiac toxicity in the treatme ...
Full textCite
Journal ArticleCurrent Oncology · January 1, 2011
Background: The efficacy of adjuvant chemotherapy with FEC-D (5-fluorouracil-epirubicin-cyclophosphamide followed by docetaxel) is superior to that with fec-100 alone in women with early-stage breast cancer. As the use of FEC-D increased in clinical practi ...
Full textCite
Journal ArticleJ Clin Oncol · February 10, 2010
PURPOSE Preclinical studies indicate that metronomic chemotherapy is antiangiogenic and synergistic with other antiangiogenic agents. We designed a phase I/II study to evaluate the safety and activity of adding dalteparin and prednisone to metronomic cyclo ...
Full textLink to itemCite
Journal ArticleCancer Chemother Pharmacol · February 2010
PURPOSE: Pemetrexed (PEM) is a novel folate antimetabolite which inhibits thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyl transferase. This phase II study was designed to assess the efficacy of Gemcitabine (GEM) and PEM ...
Full textLink to itemCite
Journal ArticleCurrent Oncology · January 1, 2010
Purpose Most male breast cancer tumours are hormone receptor- positive; the patients therefore receive endocrine therapy. There is, however, a paucity of published data on toxicities experienced by male breast cancer patients who are prescribed endocrine t ...
Full textCite
Journal ArticleOncologist · 2010
PURPOSE: Angiogenesis is an important hallmark of breast cancer growth and progression. Pazopanib, an oral small molecule inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and KIT, has activity across a rang ...
Full textLink to itemCite
Journal ArticleCurrent Oncology · January 1, 2010
Breast cancer positive for her2 (human epidermal growth factor receptor 2) is associated with a poor prognosis for patients with both early-stage and metastatic breast cancer. Trastuzumab has been shown to be effective and is now considered the standard of ...
Full textCite
Journal ArticleBreast Cancer Res Treat · November 2009
Fulvestrant use in pretreated metastatic breast cancer patients is associated with variable response rates. This study aimed to characterize these responses and to develop a prediction model to identify those patients who could potentially derive the most ...
Full textLink to itemCite
Journal ArticleClin Cancer Res · January 15, 2009
PURPOSE: Clusterin is an antiapoptotic protein activated in response to cellular stress. OGX-011 is a second-generation antisense oligonucleotide that inhibits clusterin expression. The primary objective of this phase II trial was to assess the safety and ...
Full textLink to itemCite
Journal ArticleCurrent Oncology · January 1, 2009
The role of targeted therapies in the treatment of women with breast cancer has been rapidly evolving. Trastuzumab, a monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), was the first HER2-targeted therapy that clearly demonstr ...
Full textCite
Journal ArticleCurrent Oncology · January 1, 2009
Women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer can potentially benefit in a number of ways, but the main advantage, which has been consistently demonstrated, is improved tumour resectability. Given the improve ...
Full textCite
Journal ArticleCancer Treat Rev · August 2008
Anthracyclines demonstrate significant disease activity in breast cancer and are a key component of therapy in both early and advanced disease. It has been long recognized that these agents are associated with cumulative dose-related cardiotoxicity that of ...
Full textLink to itemCite
Journal ArticleCancer · May 15, 2008
BACKGROUND: Quality indicators (QIs) are tools designed to measure and improve quality of care. The objective of this study was to assess stakeholder acceptability of QIs of end-of-life (EOL) care that potentially were measurable from population-based admi ...
Full textLink to itemCite
Journal ArticleBreast Cancer Res Treat · April 2008
BACKGROUND: A systematic review of the evidence for gemcitabine chemotherapy, alone or in combination, in women with metastatic/advanced breast cancer was undertaken in order to determine gemcitabine's role in the first-line and/or second-line or greater s ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · March 20, 2008
PURPOSE: We describe issues and outcomes in the development of a specialized, central institutional review board (IRB) for multicenter oncology protocols. Numerous authoritative bodies have called for a change to the ethics review system to better manage m ...
Full textLink to itemCite
Journal ArticleBreast Cancer Res Treat · March 2008
BACKGROUND: First- and second-line chemotherapy with anthracyclines and taxanes in metastatic breast cancer yield a modest improvement in survival with potentially significant toxicity. Subsequent lines of chemotherapy yield response rates of 20-25%, with ...
Full textLink to itemCite
Journal ArticleCurrent Oncology · January 1, 2008
Trastuzumab has been shown to be an effective therapy for women with breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2) protein. In the pivotal metastatic breast cancer trials, cardiac dysfunction was observed in women tre ...
Full textCite
Journal ArticleJ Clin Oncol · February 20, 2006
PURPOSE: Most women with breast cancer are diagnosed at an early stage and more than 80% will be long-term survivors. Routine follow-up marks the transition from intensive treatment to survivorship. It is usual practice for routine follow-up to take place ...
Full textLink to itemCite
Journal ArticleLung · 2005
Troxacitabine. a promising new L-nucleoside, inhibits DNA polymerase and leads to complete DNA chain termination. The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) conducted a phase II study to assess the efficacy and toxicity of tro ...
Full textLink to itemCite
Journal ArticleInvest New Drugs · January 2005
BACKGROUND: The primary objective of this Phase I study was to determine the maximum tolerated dose (MTD) and recommended phase II dose for Tomudex and Doxorubicin when given in combination to patients with advanced metastatic cancer. The secondary objecti ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · January 15, 2004
PURPOSE: N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine (DPPE; tesmilifene) is a novel agent that augments chemotherapy cytotoxicity in vitro and in vivo. A phase II trial combining DPPE and doxorubicin (DOX) in metastatic breast carcinoma showed increa ...
Full textLink to itemCite
Journal ArticleJ Natl Cancer Inst · April 16, 2003
BACKGROUND: In recent years, patients have indicated a desire for more information about their disease and to be involved in making decisions about their care. We developed an aid called the "Decision Board" to help clinicians inform patients with lymph no ...
Full textLink to itemCite
Journal ArticleJ Clin Oncol · February 1, 2001
PURPOSE: A multinomial stopping rule had previously been developed that incorporated both objective response and early progression into decisions to stop or continue phase II trials of anticancer agents. The purpose of this study was to apply the multinomi ...
Full textLink to itemCite
Journal ArticleAnn Oncol · January 2000
BACKGROUND: Ovarian cancer is the leading cause of death from gynecological malignancies and the fourth most frequent fatal malignancy in women. Despite improved surgical techniques as many as 20% of women with early stage disease will eventually relapse a ...
Full textLink to itemCite
Journal ArticleJournal of Clinical Oncology · January 1, 1999
Purpose: This multicenter phase II trial investigated the efficacy and toxicity of a combination of the novel intracellular histamine antagonist, N,N-diethyl-2-[4(phenylmethyl)phenoxy]ethanamine.HCl (DPPE), and doxorubicin in patients with anthracycline-na ...
Full textCite
Journal ArticleAnn Oncol · August 1996
BACKGROUND: The primary goal of phase I studies is to efficiently and accurately determine the recommended dose of a new agent for further investigation. Issues of concern ranging from the ethics of these trials to selection of starting dose and rapidity o ...
Full textLink to itemCite
Journal ArticleJ Neurooncol · April 1996
UNLABELLED: We conducted a Phase II study of PROMACE-MOPP and intrathecal (IT) therapy followed by cranial radiation in 7 patients (4 male, 3 females) with diffuse large cell lymphomas (including one T cell) involving the central nervous system (CNS). Medi ...
Full textLink to itemCite